FOXO1 and diabetes mellitus: Furthermore, inhibiting DYRK1B kinase activity using AZ191 affects FOXO1 stabilization on chromatin, improving hyperglycemia in diabetic mice, highlighting the therapeutic potential of AZ191 in diabetes treatment (Fig. 6F).